1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow MD: 30mg WVE-003: new trials by email Literature Review of MD: 30mg WVE-003 trials Research Report on MD: 30mg WVE-003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of WVE-003 in Patients With Huntington's Disease SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003 - Huntington Disease | Phase 1 / Phase 2 | Completed | Wave Life Sciences USA, Inc. | 47 | 2021-09-06 | 2025-08-12 |
Wave Life Sciences USA, Inc. (1)
Australia (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)